Mersana Therapeutics to Present at the 12th Annual Wedbush PacGrow Healthcare Conference
August 04 2021 - 8:00AM
Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage
biopharmaceutical company focused on discovering and developing a
pipeline of antibody-drug conjugates (ADCs) targeting cancers in
areas of high unmet medical need, today announced that the Company
will participate in a virtual panel presentation at the 12th Annual
Wedbush PacGrow Healthcare Conference on Wednesday, August 11th,
2021 at 2:20 p.m. ET.
A live webcast of the panel will be available on the Investors
& Media section of Mersana’s website at www.mersana.com. An
archived replay will be available for approximately 90 days
following the panel.
About Mersana Therapeutics
Mersana Therapeutics is a clinical-stage biopharmaceutical
company using its differentiated and proprietary ADC platforms to
rapidly develop novel ADCs with optimal efficacy, safety and
tolerability to meaningfully improve the lives of people fighting
cancer. Mersana’s lead product candidate, upifitamab rilsodotin
(UpRi), is a Dolaflexin ADC targeting NaPi2b and is being studied
in UPLIFT, a single-arm registration strategy in patients with
platinum-resistant ovarian cancer, as well as in UPGRADE, a Phase 1
umbrella study in combination with other ovarian cancer therapies.
UpRi is also being evaluated in the expansion portion of a Phase 1
proof-of-concept clinical study in patients with NSCLC
adenocarcinoma. XMT-1592, Mersana’s second ADC product candidate
targeting NaPi2b-expressing tumors, was created using Mersana’s
customizable and homogeneous Dolasynthen platform and is in the
dose escalation portion of a Phase 1 proof-of-concept clinical
study. The Company’s early-stage programs include XMT-1660, a
Dolasynthen ADC targeting B7-H4, as well as XMT-2056, a
STING-agonist ADC developed using the Company’s Immunosynthen
platform. In addition, multiple partners are using Mersana’s
Dolaflexin platform to advance their ADC pipelines.
Contact:
Investor & Media ContactSarah
Carmody617-844-8577scarmody@mersana.com
Mersana Therapeutics (NASDAQ:MRSN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Mersana Therapeutics (NASDAQ:MRSN)
Historical Stock Chart
From Apr 2023 to Apr 2024